Owners, management and financials
CVR: 26058708
Previous names: JUT NR. 2181 A/S
DKK 1,174,659,000
Revenue
Net result: DKK 9,727,000
ORIFARM PI A/S (100%)
CVR · view owners
Thomas Brandhof
Board: Hans Carl Bøgh-Sørensen (chair) and 2 members
CVR · view management
Active
Founded 1 April 2001
CVR · view overview
46 employees
CVR · 2018
Director registered: Thomas Brandhof
CVR · 01/02/2019
View the full event history
ORIFARM A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2001. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named JUT NR. 2181 A/S. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM PI A/S. The company has 46 employees (2018). In 2025, the company reported revenue of DKK 1,174,659,000 and a net result of DKK 9,727,000 compared with DKK 14,865,000 the year before. Equity in the 2025 report amounted to DKK 44,048,000.
Source: annual report 2025, Danish Business Authority
The financial health of ORIFARM A/S shows signs of instability, with a notable decline in both revenue and profit over the past two years. Revenue decreased from 1,575,946,000 DKK in 2023 to 1,174,659,000 DKK in 2025, while profit also fell from 18,874,000 DKK to 9,727,000 DKK in the same period. Although equity has remained relatively stable, decreasing from 76,256,000 DKK to 44,048,000 DKK, the declining profit margins raise concerns about operational efficiency. Positioned within the wholesale trade of medicinal products and healthcare items, ORIFARM A/S faces challenges that may impact its competitive standing in the industry.
AI-generated summary · Generated 29/05/2026
Selskabets formål er at foretage salg af parallelimporterede lægemidler i Danmark.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 1.2 mia. | 9.7 mio. | 148.1 mio. | 44 mio. | 37 | |
| 202401/01/2024 – 31/12/2024 | 1.2 mia. | 14.9 mio. | 150.4 mio. | 53.9 mio. | 37 | |
| 202301/01/2023 – 31/12/2023 | 1.6 mia. | 18.9 mio. | 301.8 mio. | 76.3 mio. | 37 | |
| 202201/01/2022 – 31/12/2022 | 1.4 mia. | 9.9 mio. | 421.6 mio. | 57.4 mio. | 34 | |
| 202101/01/2021 – 31/12/2021 | 1.5 mia. | 8.2 mio. | 195.4 mio. | 47.4 mio. | 40 | |
| 202001/01/2020 – 31/12/2020 | 1.2 mia. | 6.6 mio. | 195.1 mio. | 42.3 mio. | 42 | |
| 201901/01/2019 – 31/12/2019 | 1.2 mia. | 5.1 mio. | 175.3 mio. | 35.7 mio. | 38 | |
| 201801/01/2018 – 31/12/2018 | 1.3 mia. | 4.3 mio. | 194.2 mio. | 40.6 mio. | 45 | |
| 201701/01/2017 – 31/12/2017 | 1.2 mia. | 4.4 mio. | 232 mio. | 36.3 mio. | 42 | |
| 201601/01/2016 – 31/12/2016 | 1.2 mia. | 3.6 mio. | 312.4 mio. | 31.9 mio. | 72 | |
| 201501/01/2015 – 31/12/2015 | 1 mia. | 5.4 mio. | 194.8 mio. | 28.2 mio. | - | |
| 201401/01/2014 – 31/12/2014 | 1.1 mia. | 4.4 mio. | 218.9 mio. | 22.8 mio. | - | |
| 201301/01/2013 – 31/12/2013 | 1.1 mia. | 4.5 mio. | 213.8 mio. | 18.4 mio. | - |
Compared to 407 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
81 public tenders won
Showing 10 of 81 contracts
See all won contracts on UdbudsScannerSources: TED (the EU tender database) and udbud.dk
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationThe CVR number of ORIFARM A/S is 26058708.
ORIFARM A/S is owned by ORIFARM PI A/S.
The management of ORIFARM A/S consists of Thomas Brandhof.
The board of ORIFARM A/S consists of Hans Carl Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen, with Hans Carl Bøgh-Sørensen as chair.
In 2025, ORIFARM A/S reported revenue of DKK 1,174,659,000.
ORIFARM A/S had 46 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
ORIFARM A/S has won the tender "Amgros 2026 1.164.a" issued by Amgros I/S worth 3,222,720 DKK.
As of June 2, 2026, Birgitte Bøgh-Sørensen has left the board of directors of ORIFARM A/S.
ORIFARM A/S has published its annual report for 2025. Revenue came to DKK 1,174,659,000, and the net result was DKK 9,727,000.
ORIFARM A/S has won the tender "Amgros 2026 1.354.b" issued by Amgros I/S worth 8,902,028 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.295.a" issued by Amgros I/S worth 46,824,716 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.1306.b" issued by Amgros I/S worth 26,000,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.1068.a" issued by Amgros I/S worth 217,000,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.450.b" issued by Amgros I/S worth 72,960,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.1216.a" issued by Amgros I/S worth 19,794,473 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.209.a" issued by Amgros I/S worth 22,313,896 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.710.a" issued by Amgros I/S worth 91,191,236 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.708.b" issued by Amgros I/S worth 321,891,182 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.610.a" issued by Amgros I/S worth 75,600,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.1201.a" issued by Amgros I/S worth 358,514,920 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.1390.b" issued by Amgros I/S worth 23,945,273 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.1302.b" issued by Amgros I/S worth 161,990,275 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.1303.b" issued by Amgros I/S worth 4,100,779 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.1301.a" issued by Amgros I/S worth 39,781,779 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.1203.a" issued by Amgros I/S worth 368,505,024 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.1205.b" issued by Amgros I/S worth 497,443,398 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.290.b" issued by Amgros I/S worth 88,050,546 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.210.a" issued by Amgros I/S worth 102,909,186 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.604.a" issued by Amgros I/S worth 501,367,776 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.201.a" issued by Amgros I/S worth 286,787,957 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.790.b" issued by Amgros I/S worth 66,631,361 DKK.
As of October 20, 2025, Nicki Lund Kristensen has joined the board of directors of ORIFARM A/S.
ORIFARM A/S has won the tender "Amgros 2026 2.703.b" issued by Amgros I/S worth 66,045,550 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.3.b" issued by Amgros I/S worth 382,769,201 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.702.b" issued by Amgros I/S worth 22,987,384 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.704.b" issued by Amgros I/S worth 32,900,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.865.a" issued by Amgros I/S worth 1,570,800,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.165.a" issued by Amgros I/S worth 1,566,600,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.1053.b" issued by Amgros I/S worth 948,600,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.1042.b" issued by Amgros I/S worth 337,000,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.810.a" issued by Amgros I/S worth 137,104,621 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.1400.a" issued by Amgros I/S worth 4,110,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1430.b" issued by Amgros I/S worth 31,600,000 DKK.
ORIFARM A/S has published its annual report for 2024. Revenue came to DKK 1,223,777,000, and the net result was DKK 14,865,000.
ORIFARM A/S has won the tender "Amgros 2025 1.872.a" issued by Amgros I/S worth 998,250,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.407.a" issued by Amgros I/S worth 4,623,558 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.985.b" issued by Amgros I/S worth 522,750,000 DKK.
As of March 17, 2025, Hans Carl Bøgh-Sørensen has joined the board of directors of ORIFARM A/S.
As of March 17, 2025, Mads Fink Eriksen has joined the board of directors of ORIFARM A/S.
As of March 17, 2025, Erik Sandberg has left the board of directors of ORIFARM A/S.
As of March 16, 2025, Hans Carl Bøgh-Sørensen has left the board of directors of ORIFARM A/S.
ORIFARM A/S has won the tender "Amgros 2025 1.350.a" issued by Amgros I/S worth 20,097,600,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.295.a" issued by Amgros I/S worth 19,893,718 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.956.b" issued by Amgros I/S worth 143,472,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.955.b" issued by Amgros I/S worth 711,450,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.542.b" issued by Amgros I/S worth 58,800,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.351.b" issued by Amgros I/S worth 22,702,680,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1163.a" issued by Amgros I/S worth 1,644,000,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1211.b" issued by Amgros I/S worth 14,600,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.709.a" issued by Amgros I/S worth 145,756,745 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.205.a" issued by Amgros I/S worth 37,203,010 DKK.
ORIFARM A/S has won the tender "Amgros 2025 2.212.a" issued by Amgros I/S worth 14,666,754 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1208.b" issued by Amgros I/S worth 7,330,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.162.a" issued by Amgros I/S worth 1,526,400,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1402.a" issued by Amgros I/S worth 1,090,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 2.210.a" issued by Amgros I/S worth 36,886,685 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.132.b" issued by Amgros I/S worth 188,000,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 2.1310.b" issued by Amgros I/S worth 129,999,998 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1311.a" issued by Amgros I/S worth 27,850,951 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.702.b" issued by Amgros I/S worth 64,099,999 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1312.b" issued by Amgros I/S worth 1,997,154 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1201.a" issued by Amgros I/S worth 45,354,771 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1303.b" issued by Amgros I/S worth 14,267,938 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1305.a" issued by Amgros I/S worth 91,145,340 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.700.a" issued by Amgros I/S worth 313,301,544 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1301.a" issued by Amgros I/S worth 60,592,287 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1200.a" issued by Amgros I/S worth 101,036,383 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1205.a" issued by Amgros I/S worth 73,155,425 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.701.a" issued by Amgros I/S worth 176,204,140 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1202.a" issued by Amgros I/S worth 90,124,932 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1203.a" issued by Amgros I/S worth 12,911,962 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.706.b" issued by Amgros I/S worth 25,800,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 2.3.b" issued by Amgros I/S worth 359,770,187 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.703.b" issued by Amgros I/S worth 12,600,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.203.b" issued by Amgros I/S worth 17,700,001 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.550.b" issued by Amgros I/S worth 652,620,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1460.a" issued by Amgros I/S worth 35,600,000 DKK.
ORIFARM A/S has won the tender "Amgros 2024 1.585.b" issued by Amgros I/S worth 32,800,000 DKK.
ORIFARM A/S has won the tender "Amgros 2024 1.486.a" issued by Amgros I/S worth 29,200,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1173.a" issued by Amgros I/S worth 14,900,000 DKK.
ORIFARM A/S has published its annual report for 2023. Revenue came to DKK 1,575,946,000, and the net result was DKK 18,874,000.
ORIFARM A/S has won the tender "Amgros 2024 1.167.a" issued by Amgros I/S worth 291,550,000 DKK.
ORIFARM A/S has won the tender "Amgros 2024 1.1451.b" issued by Amgros I/S worth 95,200,000 DKK.
ORIFARM A/S has won the tender "Amgros 2024 1.1400.a" issued by Amgros I/S worth 1,267,971 DKK.
ORIFARM A/S has won the tender "Amgros 2024 1.472.a" issued by Amgros I/S worth 20,675,200,000 DKK.
ORIFARM A/S has won the tender "Amgros 2024 1.351.b" issued by Amgros I/S worth 19,644,800,000 DKK.
ORIFARM A/S has published its annual report for 2022. Revenue came to DKK 1,404,798,000, and the net result was DKK 9,941,000.
ORIFARM A/S has published its annual report for 2021. Revenue came to DKK 1,493,622,000, and the net result was DKK 8,190,000.
ORIFARM A/S has published its annual report for 2020. Revenue came to DKK 1,180,912,000, and the net result was DKK 6,563,000.
ORIFARM A/S has published its annual report for 2019. Revenue came to DKK 1,200,155,000, and the net result was DKK 5,096,000.
ORIFARM A/S has published its annual report for 2018. Revenue came to DKK 1,250,457,000, and the net result was DKK 4,295,000.
As of February 1, 2019, Jens Peter Nielsen has left the board of directors of ORIFARM A/S.
As of February 1, 2019, Thomas Brandhof is registered as adm. dir. of ORIFARM A/S.
As of February 1, 2019, Tine Søndergaard Jensen has stepped down as adm. dir. of ORIFARM A/S.
ORIFARM A/S has published its annual report for 2017. Revenue came to DKK 1,192,494,000, and the net result was DKK 4,424,000.
ORIFARM A/S has published its annual report for 2016. Revenue came to DKK 1,202,590,000, and the net result was DKK 3,640,000.
ORIFARM A/S has published its annual report for 2015. Revenue came to DKK 1,035,134,000, and the net result was DKK 5,442,000.
As of August 27, 2015, Jens Peter Nielsen has joined the board of directors of ORIFARM A/S.
As of August 27, 2015, Anna Rehman Linder has left the board of directors of ORIFARM A/S.
As of August 27, 2015, Tine Søndergaard Jensen is registered as adm. dir. of ORIFARM A/S.
As of August 27, 2015, Jens Peter Nielsen has stepped down as adm. dir. of ORIFARM A/S.
ORIFARM A/S has published its annual report for 2014. Revenue came to DKK 1,149,174,000, and the net result was DKK 4,431,000.
ORIFARM A/S has published its annual report for 2013. Revenue came to DKK 1,078,460,000, and the net result was DKK 4,473,000.
As of April 9, 2014, Birgitte Bøgh-Sørensen has joined the board of directors of ORIFARM A/S.
As of April 9, 2014, Erik Sandberg has joined the board of directors of ORIFARM A/S.
As of April 9, 2014, Anna Rehman Linder has joined the board of directors of ORIFARM A/S.
As of April 9, 2014, Hans Christian Eberhard Groth Teisen has left the board of directors of ORIFARM A/S.
As of April 9, 2014, Jens Peter Nielsen is registered as adm. dir. of ORIFARM A/S.
As of April 9, 2014, Erik Sandberg has stepped down as adm. dir. of ORIFARM A/S.
ORIFARM A/S has published its annual report for 2012.
As of December 21, 2012, Hans Carl Bøgh-Sørensen has joined the board of directors of ORIFARM A/S.
As of December 21, 2012, Anders Carl Norstrand has left the board of directors of ORIFARM A/S.
As of December 21, 2012, Erik Sandberg is registered as adm. dir. of ORIFARM A/S.
As of December 21, 2012, Hans Carl Bøgh-Sørensen has stepped down as adm. dir. of ORIFARM A/S.
As of July 5, 2012, Hans Christian Eberhard Groth Teisen has joined the board of directors of ORIFARM A/S.
As of July 5, 2012, Ole Ibsen has left the board of directors of ORIFARM A/S.
As of October 13, 2011, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ORIFARM A/S.
As of October 13, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of ORIFARM A/S.
As of April 15, 2008, Ole Ibsen has joined the board of directors of ORIFARM A/S.
As of April 14, 2008, Per Munk Laustsen has left the board of directors of ORIFARM A/S.
As of January 27, 2005, Anders Carl Norstrand has joined the board of directors of ORIFARM A/S.
As of January 27, 2005, John Morell Frellsen has left the board of directors of ORIFARM A/S.
As of January 27, 2005, Hans Carl Bøgh-Sørensen is registered as adm. dir. of ORIFARM A/S.
As of October 20, 2003, Per Munk Laustsen has joined the board of directors of ORIFARM A/S.
As of October 20, 2003, John Morell Frellsen has joined the board of directors of ORIFARM A/S.
As of October 20, 2003, Ole Michael Friis has left the board of directors of ORIFARM A/S.
As of October 20, 2003, Hans Carl Bøgh-Sørensen has left the board of directors of ORIFARM A/S.
As of September 12, 2003, ORIFARM PI A/S is registered as an owner of ORIFARM A/S with an ownership share of 100%.
As of May 31, 2003, Niels Thorborg has left the board of directors of ORIFARM A/S.
On January 5, 2002, the company changed its name from JUT NR. 2181 A/S to ORIFARM A/S.
As of November 1, 2001, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of ORIFARM A/S.
As of November 1, 2001, Poul Bak Revisionsfirma I/S Postboks 428 has stepped down as auditor of ORIFARM A/S.
As of November 1, 2001, Ole Michael Friis has joined the board of directors of ORIFARM A/S.
As of November 1, 2001, Niels Thorborg has joined the board of directors of ORIFARM A/S.
As of November 1, 2001, Hans Carl Bøgh-Sørensen has joined the board of directors of ORIFARM A/S.
As of November 1, 2001, Henrik Steen Jensen has left the board of directors of ORIFARM A/S.
As of November 1, 2001, Steffen Ebdrup has left the board of directors of ORIFARM A/S.
As of November 1, 2001, Erik Jensen has left the board of directors of ORIFARM A/S.
As of November 1, 2001, Erik Jensen has stepped down as director of ORIFARM A/S.
As of April 1, 2001, Poul Bak Revisionsfirma I/S Postboks 428 has been appointed auditor of ORIFARM A/S.
As of April 1, 2001, Henrik Steen Jensen has joined the board of directors of ORIFARM A/S.
As of April 1, 2001, Steffen Ebdrup has joined the board of directors of ORIFARM A/S.
As of April 1, 2001, Erik Jensen has joined the board of directors of ORIFARM A/S.
As of April 1, 2001, Erik Jensen is registered as director of ORIFARM A/S.
ORIFARM A/S was founded on April 1, 2001.
Companies in the same industry and area
CVR 17153684
CVR 25674030
CVR 44825775
CVR 46078632
CVR 31312574
